Removing toxicity

Liver toxicity or unmanageable pharmacokinetics have killed a lot of drugs over the years. But with this week's announcement of Phase I safety data for a nucleotide reverse transcriptase inhibitor that had been shelved due to toxicity, Heidelberg Pharma AG believes it now has sound evidence to prove that its Enhanced Pro-Drug Technology (EPD) platform can salvage

Read the full 576 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE